Witte, et al1616. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(7):1931-42
|
ECR |
Group A: Vitamin D3 Group B:Placebo Total: 223 patients |
A: Vitamin D3 of 4000 IU daily for one year B: Calcium-free placebo |
There was no improvement in the 6-minute walk distance, but vitamin D3 had beneficial effects on the structure and function of the left ventricle in patients under contemporary medical therapy |
Gepner D, et al1717. Gepner D, Ramamurthy R, Krueger C, Korcarz E, Binkley N, Stein J. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One. 2012;7(5):e36617
|
ECR |
Group A: Vitamin D3 Group B:Placebo Total: 114 patients |
A: Vitamin D3 2500 IU daily for four weeks B: Placebo |
There was no improvement in endothelial function, arterial stiffness or inflammation |
Bernini G, et al1818. Bernini G, Carrara D, Bacca A, Carli V, Virdis A, Rugani I, et al. Effect of acute and chronic vitamin D administration on systemic renin angiotensin system in essential hypertensives and controls. J Endocrinol Invest. 2013 Apr;36(4):216-20.
|
ECR |
Total: 38 patients |
A: Calcitriol 0.25 μg for one week B: Angiotensin II receptor antagonist and a single dose of cholecalciferol at 300,000 IU for eight weeks |
Activation of vitamin D receptor does not influence the systemic activity of the renin-angiotensin system |
Nsengiyumva V, et al1919. Nsengiyumva V, Fernando M, Moxon J, Krishna S, Pinchbeck J, Omer S, et al. The association of circulating 25-hydroxyvitamin D concentration with peripheral arterial disease: A meta-analysis of observational studies. Atherosclerosis. 2015; 243(2):645-51.
|
RS |
Total: 8 articles with 529 participants |
Vitamin D3 in the following posologies: 100,000 IU single dose for 8 weeks 200,000 IU single dose for 16 weeks 100,000 IU single dose for 16 weeks 2000 IU daily for 16 weeks 4000 IU daily for 12 weeks 2500 IU daily for 4 months, 5000 IU daily for 12 weeks Only one study described the use of paracalcitriol capsule in the dosage of 2 μg |
More clinical trials are necessary to confirm or reject the benefit of vitamin D3 in endothelial dysfunction |
Whitham, et al2323. Witham MD, Ireland S, Houston JG, Gandy SJ, Waugh S, Macdonald M, et al. Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. Hypertension. 2014 Apr; 63(4):706-12.
|
ECR |
Group A: Patients using 3 antihypertensive agents submitted to vitamin D3 therapy Group B: Placebo Total: 68 participants |
A: Vitamin D3 at 100,000 IU every two months B: Placebo |
No reduction in blood pressure or left ventricular mass in patients with resistant hypertension |